Compare YJ & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YJ | VRAX |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3M | 2.3M |
| IPO Year | 2019 | 2021 |
| Metric | YJ | VRAX |
|---|---|---|
| Price | $3.54 | $3.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | ★ 4.7M | 470.4K |
| Earning Date | 03-27-2026 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.10 |
| 52 Week High | $13.97 | $13.19 |
| Indicator | YJ | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 65.34 | 55.43 |
| Support Level | $1.38 | $0.19 |
| Resistance Level | $13.97 | $4.75 |
| Average True Range (ATR) | 1.49 | 0.29 |
| MACD | 0.21 | 0.01 |
| Stochastic Oscillator | 19.18 | 31.65 |
Yunji Inc is a social e-commerce platform in China using a membership-based model that leverages the power of social interaction. The group offers high-quality products at attractive prices and incentivizes members to promote its platform and share products with their social contacts. It empowers prime emerging brands and manufacturers with a deep understanding of market trends and customer behavior to produce high-quality products to meet the demands of members. The company also developed several private labels in the mass consumption field, which are sold on its own platform as well as offered and sold through external channels. It operates in the PRC, and substantially all the Group's revenue is derived from within the PRC.
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.